Print Page     Close Window     

SEC Filings

10-K
SERES THERAPEUTICS, INC. filed this Form 10-K on 03/06/2019
Entire Document
 

 

To agree that this Letter Agreement accurately reflects our mutual agreement, please execute and return to me a copy of this Letter Agreement.

 

By:

/s/ Roger J. Pomerantz

 

Roger J. Pomerantz, MD, FACP

 

President, CEO and Chairman

 

Seres Therapeutics, Inc.

 

 

Agreed to this    1    day of November, 2018

 

 

By:

/s/ Claudio Kuoni

 

 

Printed Name:

Claudio Kuoni

 

 

Title:

General Counsel Nestlé Health Science

NESTEC LTD.

 

5

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.


© Seres Therapeutics. All Rights Reserved.